Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
Clinical trial NCT03532698 · UNKNOWN
Trial details
- NCT number
- NCT03532698
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2020-08-01
- Primary completion
- 2021-12-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.